Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Multiple myeloma and neurotoxicity: Patient-reported and physician-recorded findings from the German prospective TLN Registry and the LyTox project.

Hurtz, H.-J., Knauf, W., Hutzschenreuter, U., Mittermüller, J., Grugel, R., Harde, J., Boller, E., Hartmann, H., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P861), 286–287. doi:10.1159/000368945

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2014
Real-life treatment of patients with advanced pancreatic cancer in Germany – data from the clinical registry pancreatic cancer (TPK).

Hegewisch-Becker, S., Hofheinz, R.-D., Hartmann, H., Kopfmann, S., Marschner, N., 2014.

Oncol Res Treat 37(Suppl.5)(P274), 86. doi:10.1159/000368945

Abstract

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2014
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of RP, Oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study.

Hegewisch-Becker, S., Arnold, D., Lerchenmüller, C., Killing, B., Depenbusch, R., Steffens, C.-C., Al-Bartan, S.-E., Lange, T., Dietrich, G., Stoehlmacher, J., Reinacher-Schick, A., Tannapfel, A., Quidde, J., Hinke, A., Schmoll, H.-J., Graeven, U., 2014.

Oncol Res Treat 37 (Suppl.5)(V327), 99 doi:10.1159/000368945

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
AIO KRK 0207
2014
Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st.

Bruch, H.-R., Aldaoud, A., Klausmann, M., Hansen, R., Losem, C., Frank, M., Straßl, L., Ruffert, K., 2014.

Haematologica 99 (suppl 1) (PB1504).

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: Haematologica
Be-Cell-1st
2014
Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in treatment routine: Interim results of the non-interventional study Be-CeLL1st.

Ruffert, K., Aldaoud, A., Klausmann, M., Bruch, H.-R., Hansen, R., Losem, C., Frank, M., Straßl, L., 2014.

Oncol Res Treat 37(suppl 5)(P194), 53–54. doi:10.1159/000368945

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
Be-Cell-1st
2014
Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO).

Bergmann, L., Goebell, P., Kloß, S., Schirrmacher-Memel, S., Warnack, W., Kube, U., Scheffler, M., Doehn, C., Marschner, N., Rosé, C., Herrmann, E., 2014.

Oncol Res Treat 37 (suppl.5)(P282), 89. doi:10.1159/000368945

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
EVERPRO
2014
Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC).

Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013.

Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
CARIN
2013
Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA.

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Onkologie
PIAZA
2013
Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

van de Water, W., Seynaeve, C., Bastiaannet, E., Markopoulos, C., Jones, S.E., Rea, D., Hasenburg, A., Putter, H., Hille, E.T.M., Paridaens, R., de Craen, A.J.M., Westendorp, R.G.J., van de Velde, C.J.H., Liefers, G.-J., 2013.

Oncologist 18, 8–13. doi:10.1634/theoncologist.2012-0315

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncologist
TEAM
2013
Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists – outcome data from the TMK Registry.

Tesch, H., Däßler, K., Müller-Hagen, S., Kruggel, L., Jänicke, M., Marschner, N., 2013.

Onkologie 36 (suppl 7)(V358), 98. doi:10.1159/000356365

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Onkologie
TMK
2013